West Family Investments Inc. Acquires Shares of 17,830 Takeda Pharmaceutical Company Limited (NYSE:TAK)

West Family Investments Inc. bought a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 17,830 shares of the company’s stock, valued at approximately $254,000.

Other hedge funds have also modified their holdings of the company. EverSource Wealth Advisors LLC raised its position in Takeda Pharmaceutical by 38.6% in the second quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock worth $43,000 after acquiring an additional 859 shares in the last quarter. Hexagon Capital Partners LLC increased its holdings in shares of Takeda Pharmaceutical by 34.3% in the 3rd quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company’s stock valued at $63,000 after purchasing an additional 1,129 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of Takeda Pharmaceutical in the second quarter valued at about $59,000. Blue Trust Inc. boosted its holdings in Takeda Pharmaceutical by 74.0% during the second quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock worth $76,000 after buying an additional 2,330 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in Takeda Pharmaceutical by 136.1% during the third quarter. GAMMA Investing LLC now owns 6,295 shares of the company’s stock worth $90,000 after buying an additional 3,629 shares during the period. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Price Performance

TAK stock opened at $13.62 on Wednesday. The firm has a 50 day moving average of $14.19 and a 200-day moving average of $13.84. Takeda Pharmaceutical Company Limited has a 12-month low of $12.57 and a 12-month high of $15.08. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64. The company has a market cap of $43.34 billion, a price-to-earnings ratio of 23.48, a PEG ratio of 0.26 and a beta of 0.54.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.